华润医药脱手投资十年的口服胰岛素

Core Viewpoint - China Resources Pharmaceutical announced the potential sale of approximately 17.87% equity in Tianmai Biotechnology, with a valuation of nearly 8 billion yuan for Tianmai [1] Group 1: Company Actions - China Resources Pharmaceutical's subsidiary has initiated the sale process through the Shanghai United Assets and Equity Exchange, with a starting price of about 1.42 billion yuan [1] - The company currently holds less than 30% equity in Tianmai Biotechnology [1] - The relationship between China Resources Pharmaceutical and Tianmai Biotechnology began in 2016, with an investment made shortly after the company's IPO [2][7] Group 2: Market Context - The insulin market was valued at approximately 19 billion yuan in public medical institutions in 2016, with significant sales from major players [4] - Tianmai Biotechnology has potential in the oral insulin market, which could cater to a large patient base [5] - The company has faced challenges, including delays in product approvals and market competition, particularly with the introduction of national insulin procurement policies [8] Group 3: Financial Performance - China Resources Pharmaceutical's revenue and net profit have been declining, with projected revenues of 246.475 billion yuan, 259.475 billion yuan, and 132.716 billion yuan for 2023, 2024, and the first half of 2025, respectively [10] - The company has been divesting assets to streamline operations, including significant stakes in various subsidiaries [11]